In2ita A1c | Clia Waived Diagnostic Devices

Important News Regarding Medicare Reimbursement for in2it A1C Testing

Effective January 2007, Medicare CPT code 83037QW was approved for A1C tests performed in a physician's office using an assay cleared by the FDA for home use. The National Limitation Amount is $21.06, a 55% increase over CPT code 83036QW. Individual state rates may vary.

in2it™  A1C

Be the Difference
With Fast, Accurate Results

The in2it™  A1C Analyzer offers simple, accurate A1C testing at the point of care. When you are working with patients to manage their diabetes, you need an A1C test that you both can rely on. That means precise results delivered quickly and easily at an attractive reimbursement rate. The in2it™  is designed with those needs in mind, delivering accurate results in just minutes to help you be the difference for every diabetic patient you care for.

• Easy, on-site testing 
• CLIA waived* allows existing staff to perform the test
• Full automation simplifies training, use and lets the operator walkway during testing
• Small fingerstick sample for greater convenience and patient comfort
• Better patient care 
• Results are delivered while your patients wait, enabling same-visit consultations for better patient compliance
• Calibrated to the Diabetes Control and Complications Trial (DCCT) standard for laboratory accurate results
• Laboratory precision provides reproducible results you can trust
• Flexible, to meet all testing situations 
• PC connectivity simplifies result handling and storage
• Ability to capture patient and operator identification provides full result traceability
• Adhesive-backed printed reports eliminates transcription errors and provides permanent result back-up
• Higher Reimbursement 
• Qualifies for CPT code 83037QW, with a national limit of $21.05
• Each test generates an additional $7.50 compared to CPT code 83036QW

*510(k) cleared for prescription home use and, accordingly, is CLIA waived.